VHH Antibodies Modulating IL-2 Receptor Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for modulating interleukin-2 (IL-2) and its receptors, particularly the high affinity IL-2Rα/IL-2Rβ/γc complex, face challenges such as poor specificity, short in vivo half-life, immunogenicity, and undesirable side effects, limiting their effectiveness in treating autoimmune disorders and cancer.
Innovation Solution
Development of binding molecules, specifically VHH domain antibodies that target the IL-2Rα, IL-2Rβ, and γc chains, allowing for the selective modulation of T regulatory cells by binding to the IL-2Rα/IL-2Rβ/γc receptor complex without inducing antibodies against mutant IL-2, thereby providing a more specific and potent approach for treating autoimmune disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If low dose IL-2 therapy is used to preferentially stimulate Tregs, then specificity for Treg cells is improved, but in vivo half-life becomes short and immunogenicity increases
Solution Approach 1:
The patent modifies the IL-2 cytokine by introducing amino acid substitutions (such as L12Q, L12N, L12S mutations) to create mutant IL-2 molecules with altered properties. These parameter changes in the cytokine structure extend in vivo half-life while maintaining or enhancing Treg cell specificity, resolving the contradiction between short half-life and therapeutic effectiveness.
2Productivity
If higher dose IL-2 is used to stimulate T effector cells, then therapeutic effect on cancer is improved, but undesirable side effects such as vascular leak syndrome increase
Solution Approach 1:
The mutant IL-2 molecules are designed with specific amino acid changes (e.g., L12Q, L12N, L12S substitutions) that locally alter the cytokine's interaction properties. This enables selective binding to Treg cells expressing high levels of IL-2Rα/IL-2Rβ/IL-2Rγ complex, achieving cancer therapeutic effects while avoiding the vascular leak syndrome associated with non-specific high-dose IL-2 therapy.
Solution Approach 2:
By changing the amino acid parameters of IL-2 (specifically positions 12 and other residues), the patent creates molecules with modified affinity profiles that preferentially engage Treg cells. This parameter modification allows therapeutic efficacy at lower doses without the harmful side effects of high-dose IL-2.
3Measurement precision
If mutant forms of IL-2 are developed with increased specificity for high affinity IL-2Rα/IL-2Rβ/γc receptor complex, then specificity is improved, but off-target binding to CD25+ cells occurs
Solution Approach 1:
The patent introduces specific amino acid substitutions (L12Q, L12N, L12S and others) to modify the IL-2 molecule's binding characteristics. These parameter changes enhance specificity for the tri-chain IL-2Rα/IL-2Rβ/IL-2Rγ complex while reducing off-target binding to CD25+ cells, resolving the contradiction between improved specificity and off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The VHH domain antibodies effectively target and stimulate T regulatory cells, offering improved specificity and reduced side effects, enhancing the treatment of autoimmune disorders and inflammatory conditions by modulating the immune response.
Implementation Method 1
binding molecules, specifically VHH domain antibodies that target the IL-2Rα, IL-2Rβ, and γc chains, allowing for the selective modulation of T regulatory cells by binding to the IL-2Rα/IL-2Rβ/γc receptor complex
Data Source
AI summary
The present invention provides binding molecules, particularly antibodies, or antigen-binding portions thereof, which bind to the IL-2 receptor and selectively activate regulatory T cells. The invention further relates to compositions and therapeutic methods for use of these binding molecules for the treatment and/or prevention of autoimmune diseases, and/or other conditions responsive to therapy that is effective to a selective increase in numbers and activation of regulatory T cells over effector T cells.